| Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
Characteristics | Odds ratio [95% CI] | Pvalue | Odds ratio [95% CI] | Pvalue |
Week 4 | Â | Â | Â | Â |
  EPO rs1617640 (GG vs. TT/TG) | 1.66 [0.92 – 2.94] | 0.088 | 2.17 [1.09 – 4.30] | 0.025 |
  ITPA rs1127354 (additive) | 0.35 [0.15 – 0.71] | 0.007 | 0.32 [0.13 – 0.70] | 0.007 |
  Age (years) | 0.97 [0.95 – 0.99] | 0.0085 | 0.97 [0.95 – 1.00] | 0.02 |
  Sex (female vs. male) | 0.75 [0.44 – 1.26] | 0.285 | 1.64 [0.88 – 3.07] | 0.12 |
  Baseline Hb (g/dl) | 2.24 [1.76 – 2.92] | < 0.001 | 2.50 [1.91 – 3.34] | < 0.001 |
  RBV starting dose* | 2.49 [1.03 – 7.34] | 0.011 | 2.50 [1.03 – 7.34] | 0.036 |
Week 12 | ||||
  EPO rs1617640 (GG vs. TT/TG) | 1.57 [0.92 – 2.70] | 0.064 | 1.97 [1.07 – 3.66] | 0.029 |
  ITPA rs1127354 (additive) | 0.60 [0.35 – 1.01] | 0.058 | 0.58 [0.32 – 1.03] | 0.067 |
  Age (years) | 0.97 [0.95 – 0.99] | 0.002 | 0.97 [0.95 – 0.99] | 0.004 |
  Sex (female vs. male) | 0.86 [0.55 – 1.33] | 0.49 | 1.75 [1.04 – 2.99] | 0.084 |
  Baseline Hb (g/dl) | 1.90 [1.55 – 2.35] | < 0.001 | 2.08 [1.67 – 2.64] | < 0.001 |
  RBV starting dose* | 2.09 [1.20 – 3.79] | 0.011 | 2.18 [1.17 – 4.20] | 0.016 |